Trials / Terminated
TerminatedNCT05623345
Psoriatic Arthritis Study of Izokibep
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Active Psoriatic Arthritis
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 351 (actual)
- Sponsor
- ACELYRIN Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Izokibep is a potent and selective inhibitor of interleukin (IL)-17A that is being developed for treatment of psoriatic arthritis (PsA). This study will evaluate the efficacy of izokibep in subjects with PsA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Izokibep | Biologic: IL-17A inhibitor Form: Solution for injection Route of administration: Subcutaneous (SC) |
| DRUG | Placebo to izokibep | Form: Solution for injection Route of administration: Subcutaneous (SC) |
Timeline
- Start date
- 2022-11-21
- Primary completion
- 2023-11-30
- Completion
- 2024-08-08
- First posted
- 2022-11-21
- Last updated
- 2025-05-23
- Results posted
- 2025-05-23
Locations
71 sites across 8 countries: United States, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05623345. Inclusion in this directory is not an endorsement.